Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients

Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism

“…It is known that certain drugs can be rapidly metabolized by the CDA enzyme, which can affect their bioavailability and efficacy ( Lavelle et al, 2012 ). In the context of chemotherapy, CDA plays a significant role ( Abbaspour et al, 2023 ), since it metabolizes several chemotherapeutic drugs, including gemcitabine ( Pellicer et al, 2017 ). Gemcitabine interferes with DNA synthesis and replication either by inhibiting enzymes involved in the synthesis of nucleic acid precursors or by misincorporation of nucleic acids into DNA or RNA macromolecules ( Ciccolini et al, 2016 ).…”

Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing

“…Consequently, low expression of DCK is associated with a significant shorter median survival in PDAC patients receiving gemcitabine [ 10 ]. Gemcitabine inactivation is facilitated by cytidine deaminase (CDA) which converts gemcitabine to 2′,2′-difluorodeoxyuridine and cancer patients with lower serum levels of CDA show a significantly longer survival than patients with high CDA levels [ 11 , 4 ]. Moreover, a previous publication from our group had shown that overexpression of cytosolic 5′-nucleotidase 1 A (NT5C1A) increases gemcitabine resistance by decreasing intracellular amounts of dFdCTP [ 12 ].…”